This 2010 study surveyed 199 complementary and alternative medicine (CAM) practitioners, revealing that 172 administered high-dose intravenous vitamin C (IVC) to over 20,000 patients in 2006 and 2008. The average dose was 28 grams every 4 days, totaling 22 treatments per patient. Commonly treated conditions included infections, cancer, and fatigue.
This scoping review evaluated the potential harms associated with high-dose intravenous (IV) vitamin C therapy in adults by analyzing 74 studies involving 2,801 patients. High-dose vitamin C was defined as ≥6 g/day, ≥75 mg/kg/day, or ≥3 g/m²/day, with a median dose of 22.5 g/day (IQR: 8.25–63.75 g/day). At least 932
This phase I-II clinical trial evaluated the safety, pharmacokinetics, and preliminary efficacy of high-dose intravenous vitamin C (IVC) combined with standard or off-label chemotherapy in 14 patients with advanced, treatment-refractory cancer. Patients were selected based on an expected response rate of less than 33% to chemotherapy alone. The IVC doses
This study investigated the effects of high-dose intravenous vitamin C (ascorbate) on the sensitivity of ovarian cancer to chemotherapy and its potential to reduce chemotherapy-induced toxicity. The research involved both in vitro (cell culture) and in vivo (animal model) experiments. The findings suggested that pharmacologic concentrations of ascorbate can enhance
This review article re-examines the potential role of high-dose vitamin C (ascorbic acid) therapy in treating advanced cancer. It discusses the historical controversy surrounding vitamin C’s efficacy in cancer treatment and highlights emerging evidence that suggests ascorbate therapy could be effective if appropriate protocols are employed. The authors emphasize the
A phase 1 clinical trial at the University of Iowa evaluated high-dose intravenous vitamin C (IVC) in patients with glioblastoma multiforme (GBM) and non-small cell lung cancer (NSCLC). IVC infusions aimed to raise plasma vitamin C levels to 20,000 μM, significantly above normal levels (~70 μM). The treatment was well-tolerated,
This study investigated the clinical impact of intravenous ascorbic acid (vitamin C) and hydrogen peroxide on 56 patients experiencing moderate to severe joint pain following chikungunya virus infection. Each patient received a single IV infusion of 25–50 grams of ascorbic acid and 3 cc of 3% hydrogen peroxide. Pain was
This 2015 clinical review titled “Ozone Therapy: A Critical Physiological and Diverse Clinical Evaluation with Regard to Immune Modulation, Anti-Infectious Properties, Anti-Cancer Potential, and Impact on Anti-Oxidant Enzymes” (Open Journal of Molecular and Integrative Physiology, DOI: [10.4236/ojmip.2015.53004*) examined the physiological mechanisms and clinical applications of ozone therapy, particularly major autohemotherapy.
This study evaluates the use of Viscum album extract (Isorel) as an adjuvant cancer biotherapy, reporting its benefits in combination with conventional treatments like surgery and radiotherapy. The study found that Isorel helped prevent tumor recurrence in 47% of patients, led to tumor regression in 38%, and showed no health
This systematic review (Forschende Komplementärmedizin, 2009, PMID: 19729932) evaluated 18 clinical trials involving over 6,800 patients to assess the efficacy and safety of standardized mistletoe (Viscum album) preparations as complementary cancer therapy. While the quality of the included studies was generally low and too heterogeneous for meta-analysis, the findings consistently
